Fig. 5.

The effects of levistolide A on reducing Tau phosphorylation via GSK signaling pathway. (a, b) Expression levels of GSK-3α/β and p-GSK-3α/β protein in the cortex tissue of APP/PS1 Tg mice. GAPDH was used as internal control. Data represent the mean ± SD (n > 3), *p < 0.05, **p < 0.01, ***p < 0.001, compared with the vehicle-treated APP/PS1 Tg mice. (c, d) Western blots showing the protein levels of GSK-3α/β and p-GSK-3α/β protein in the N2a/APP695swe cells. (e) Western blots showing the protein levels including total-Tau, p-Tau (Thr181, Ser396, Ser416). GAPDH was used as internal control. (f–i). Quantitative analysis of the results shown in (e). Data represent the mean ± SD (n > 3), *p < 0.05, **p < 0.01, ***p < 0.001, compared with the vehicle